7 active not recruiting, 6 completed, 3 recruiting. 10 Phase 3, 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Active not recruiting 7, Recruiting 3 |
| Phase 2 | 5 | Completed 4, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
Follow JNJ-77242113: new trials by email Literature Review of JNJ-77242113 trials Research Report on JNJ-77242113
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease Icotrokinra, Placebo - Crohn Disease | Phase 2 / Phase 3 | Recruiting | Janssen Research & Development, LLC | 1092 | 2025-10-03 | 2026-09-25 |
| A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis Icotrokinra, Placebo - Colitis, Ulcerative | Phase 3 | Recruiting | Janssen Research & Development, LLC | 882 | 2025-10-01 | 2026-09-25 |
| A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis JNJ-77242113, Matching Placebo to JNJ-77242113, Ustekinumab - Plaque Psoriasis | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 752 | 2025-04-15 | 2026-09-25 |
| A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis Icotrokinra, Placebo, Active reference comparator - Arthritis, Psoriatic | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 552 | 2025-02-21 | 2026-09-25 |
| A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis Icotrokinra, Placebo - Arthritis, Psoriatic | Phase 3 | Recruiting | Janssen Research & Development, LLC | 750 | 2025-01-09 | 2026-09-25 |
| A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib - Plaque Psoriasis | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 731 | 2024-03-09 | 2026-09-28 |
| A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis JNJ-77242113 - Generalized Pustular Psoriasis, Erythrodermic Psoriasis | Phase 3 | Active not recruiting | Janssen Pharmaceutical K.K. | 19 | 2024-02-09 | 2026-09-28 |
| A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib - Plaque Psoriasis | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 774 | 2024-01-17 | 2026-09-28 |
| A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) JNJ-77242113, Placebo - Plaque Psoriasis | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 311 | 2023-10-12 | 2026-09-25 |
| A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis JNJ-77242113, Placebo - Plaque Psoriasis | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 684 | 2023-10-12 | 2026-09-28 |
| A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis JNJ-77242113, Placebo - Colitis, Ulcerative | Phase 2 | Completed | Janssen Research & Development, LLC | 252 | 2023-10-09 | 2026-04-13 |
| A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants JNJ-77242113 - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 30 | 2023-02-14 | 2023-06-05 |
| A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis JNJ-77242113, Placebo - Plaque Psoriasis | Phase 2 | Completed | Janssen Research & Development, LLC | 90 | 2022-06-13 | 2026-05-05 |
| A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis JNJ-77242113 - Plaque Psoriasis | Phase 2 | Completed | Janssen Research & Development, LLC | 227 | 2022-06-10 | 2026-06-01 |
| A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis JNJ-77242113, Placebo - Plaque Psoriasis | Phase 2 | Completed | Janssen Research & Development, LLC | 255 | 2022-02-03 | 2026-02-13 |
| A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants JNJ-77242113, Placebo - Healthy | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 36 | 2021-10-25 | 2025-02-03 |
Arthritis, Psoriatic (2) · Colitis, Ulcerative (2) · Crohn Disease (1) · Psoriasis (1)
Janssen Research & Development, LLC (14) · Janssen Pharmaceutical K.K. (2)
Germany (13) · Poland (13) · Spain (13) · United States (13) · Canada (12) · Japan (11) · Hungary (10) · Taiwan (10) · United Kingdom (10) · Argentina (9) · Australia (9) · South Korea (9) · China (7) · France (7) · Brazil (6)
PMID 40976249, PMID 41424381, PMID 38324484, PMID 39971605, PMID 41191932, PMID 41191940, PMID 42874103
2023 (4), 2025 (2)